Skip to main content
. 2021 Mar 18;22(5):e51280. doi: 10.15252/embr.202051280

Figure 2. Cisplatin activation of TLR4 is independent of the TLR4 co‐receptor, MD‐2.

Figure 2

  1. IL‐8 secretion in HEK cells stably expressing hTLR4 but not MD‐2 (HEK‐isoTLR4), transfected with empty vector (EV) or MD‐2 and left untreated (nil) or treated with 1 ng/ml LPS, 200 µM nickel chloride, 2 µg/ml HMGB1, 100 µM platinum(II) chloride, 100 µM platinum(IV) chloride, or 25 µM cisplatin (n = 3 or 4 independent biological replicates).
  2. Fold IL‐8 secreted (relative to nil treatment) in MD‐2‐deficient HeLa cells treated with 10 or 100 ng/ml LPS or 25 µM cisplatin (n = 4 independent biological replicates).
  3. IL‐8 secretion in HeLa cells transfected with non‐targeting (siNT) or TLR4‐targeting (siTLR4) siRNA and left untreated (nil), or treated with 30 µM cisplatin (n = 3 independent biological replicates). Mock cells were not subject to siRNA treatment prior.

Data Information: Actual individual data are plotted as box (25th and 75th percentile borders; median central band) with Tukey whiskers (A, C) or mean and standard deviation (B). Statistical analyses were determined in comparison to nil treatments using 2‐way (A, C) or one‐way (B) ANOVA. ns, not significant; *P < 0.05; ****P < 0.0001 (Dunnett’s test).

Source data are available online for this figure.